Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
Terminated
Astellas Pharma Inc
Phase 2
2002-12-01
The purpose of this study is to evaluate the safety and effectiveness of micafungin in
combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU
Terminated
Astellas Pharma Inc
Phase 3
2003-01-01
The purpose of this study is to determine the efficacy and safety of intravenous micafungin
versus placebo as prophylactic therapy for invasive fungal infections in patients in the
intensive care unit considered to be at high risk.
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
Completed
Astellas Pharma Inc
Phase 3
2004-09-01
The purpose of the study is to determine the safety and effectiveness of two dose levels of
micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
Completed
Astellas Pharma Inc
Phase 3
2003-01-01
The purpose of this study is to determine the efficacy and safety of micafungin (FK463)
versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic
patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and
pediatric patients.
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Completed
Astellas Pharma Inc
Phase 1
2007-10-01
Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an
antifungal drug. Safety and drug blood levels will be assessed
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
